Furthermore, this investigation sheds some light on the strong rationale regarding the beneficial combination of VEGF-targeted therapeutics with immunotherapy to enhance the clinical efficacy and mitigate the drug resistance seen with single-agent use in the combat against cancers. This evidence concerns the gene VEGFA and cancer.